Cure My Disease

Don't miss your cure!

 Log in / Sign up

Microtransplant without immune drugs shows promise for leukemia patients too sick for standard transplant

NCT ID NCT03232268

Disease control Sponsor: Institut Paoli-Calmettes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new type of stem cell transplant called a microtransplant in 25 people with myeloid blood cancers (like leukemia) who were too old or frail for a standard transplant. Unlike a regular transplant, this one used stem cells from a partially matched family donor and did not give patients strong immune-suppressing drugs. The main goal was to see if this approach was safe, especially whether it would cause graft-versus-host disease (GVHD), a serious side effect where donor cells attack the patient's body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HLA-mismatched hematopoietic stem cells (microtransplant)
What this could lead to
If this approach works, it could offer a safer transplant option for older or frail patients with blood cancers who cannot have a standard transplant.
What could go wrong
This is a very early, small phase 1 trial with only 25 people. The main risk is graft-versus-host disease (GVHD), even without immunosuppression. It may not work or be safe for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

25 people

The number who actually took part.

Started

Mar 2018

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age\> or = 65 years with a myeloid hemopathy in Complete Remission or Complete remission with incomplete hematological recovery or Age\<65 years with an ineligibility to allograft (contraindication to conditioning) * HLA-partially matched family donors * Affiliated to(or beneficiary of) the Social Security * Informed consent signed Exclusion Criteria: * AML3 * Previous Hematopoietic Stem Cell TRansplantation * Uncontrolled infection -PS\>3 -Other progressive cancer * Psychiatric disease * Vulnerable person or unable to provide informed consent * Emergency * Unable to comply with required study follow up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia Myelodysplastic syndromes

Contacts and locations

Locations

  • Institut Paoli Calmettes

    Marseille, Bouches du Rhône, 13009, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.